

Introduction



PubCoDe Features

Graphical Data Extraction Workflow

PubCoDe assists research scientists in extracting data from running text, tables and plots in publications.

Challenges during scientific data curation:

- Manual process of finding relevant data is tedious, and error-prone
- Extraction of precise data points from graphical image is difficult
- Selective extraction of data from tables in the document is difficult
- Validation of the extracted data is tedious



Intuitive Drag

Search and Highlight

Data Extraction from Table

treatment

KPS (<80 versus ≥80)

Patients were stratified according to their KPS (<80 versus ≥80) and randomized 1:1:1 to 1 of the 3 parallel treatment arms: PFE + CIL1W, PFE + CIL2W, and PFE (Figure 1). See supplementary Data, available at *Annals of Oncology* online for further details on the randomization process.

Cetuximab was given on days 1, 8, and 15 of each 3-week cycle (initial dose of 400 mg/m² iv over 2 h followed by 250 mg/m² over 1 h). In the PFE + CIL1W arm, cilengitide 500 mg was administered on days 1–4 and cilengitide 2000 mg on days 8 and 15; in the PFE + CIL2W arm, cilengitide 2000 mg was given on days 1, 4, 8, 11, 15, and 18 of every cycle. Cilengitide was administered as 1-h iv infusion starting 1 h post-cetuximab treatment.

Search

Select File: E:\PubCoDe\Samples\1. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or.pdf Browse...

Search Text: carcinoma|cetuximab Highlight Text

Search Criteria: ☐ Whole Word Only ☐ Case Sensitive Reset Search

Search Status:

Search Text	Whole Word	Case Sensitive	# Exact Matches	# Near Matches
carcinoma	☐	☐	11	0
cetuximab	☐	☐	27	2

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

Patients at Risk																	Patients
TPF-CRT	155	123	87	66	61	57	51	37	30	24	17	12	8	5	2	0	123
PF-CRT	156	130	87	66	58	49	43	39	32	26	20	13	7	5	3	0	87
CRT	128	97	70	50	44	38	37	36	31	23	19	14	10	6	0	0	66
																	61
																	57
																	51
																	37
																	30
																	24
																	17
																	12
																	8
																	5
																	2
																	0

Select Table Rows

Enter # Rows : 3

☐ Select All Rows

Select Row Numbers: 1,2,3


☒ Transpose Cells

OK

Data Farming from Graphs

Links for Extraction Validation

Conclusion



Reference	Phase	Treatment Arm	patients
Cisplatin, 5-fluorouracil, and cetuximab (PFE)	phase I/II	PFE + CIL1W	62
	phase I/II	PFE + CIL1W	51
	phase I/II	PFE + CIL1W	42
	phase I/II	PFE + CIL1W	25
	phase I/II	PFE + CIL1W	16
	phase I/II	PFE + CIL1W	9
	phase I/II	PFE + CIL1W	6
	phase I/II	PFE + CIL1W	2
	phase I/II	PFE + CIL1W	0
	phase I/II	PFE + CIL1W	0
	phase I/II	PFE + CIL1W	0
	phase I/II	PFE + CIL1W	0

